Advancements in cardiac gene editing are poised to reshape the landscape of cardiovascular medicine. This groundbreaking field involves the precise modification of the genetic code within cardiac cells, offering a revolutionary approach to addressing the root causes of heart diseases. Molecular tools such as CRISPR-Cas9 are at the forefront, enabling researchers to target and edit specific genes linked to cardiovascular conditions. This transformative technology holds the potential to usher in personalized therapeutic interventions, opening new vistas for treating congenital heart disorders, genetic predispositions, and various cardiovascular ailments. Although still in the nascent stages of development, cardiac gene editing represents a cutting-edge avenue that not only enhances our understanding of cardiac health but also holds immense promise for pioneering tailored treatments for individuals with diverse cardiovascular conditions.
Title : Investigating the long-term follow up of atrial septal device closures in wales and england: A comparative analysis with major adverse cardiovascular Events (MACE)
Meera Gopinath, Cardiff University Medical school, United Kingdom
Title : An adult case of polysplenia syndrome associated with sinus node dysfunction
Apoorva Tripathi, Oxford University Hospitals, United Kingdom
Title : A unique cell-driven phenomenon in the heart and the promising future of the innovative translational tools to manage cardiac self-renewal and regeneration
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Personalized and precision medicine (PPM) as a unique healthcare model through biodesign-driven translational applications and cardiology-related healthcare marketing to secure the human healthcare and biosafety
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Yasser’s criterion of inferior ST-segment discrepancy deviations in AF with aberrancy and Sgarbosa criteria - a new cardiovascular discovery and management - a case report
Yasser Mohammed Hassanain Elsayed, Egyptian Ministry of Health, Egypt